Literature DB >> 31167922

A Novel Phenotype Links HIV-1 Capsid Stability to cGAS-Mediated DNA Sensing.

Mohammad Adnan Siddiqui1, Akatsuki Saito1, Upul D Halambage2, Damien Ferhadian1, Douglas K Fischer3, Ashwanth C Francis4, Gregory B Melikyan4,5, Zandrea Ambrose3, Christopher Aiken2, Masahiro Yamashita6.   

Abstract

The HIV-1 capsid executes essential functions that are regulated by capsid stability and host factors. In contrast to increasing knowledge on functional roles of capsid-interacting host proteins during postentry steps, less is known about capsid stability and its impact on intracellular events. Here, using the antiviral compound PF-3450074 (PF74) as a probe for capsid function, we uncovered a novel phenotype of capsid stability that has a profound effect on innate sensing of viral DNA by the DNA sensor cGAS. A single mutation, R143A, in the capsid protein conferred resistance to high concentrations of PF74, without affecting capsid binding to PF74. A cell-free assay showed that the R143A mutant partially counteracted the capsid-destabilizing activity of PF74, pointing to capsid stabilization as a resistance mechanism for the R143A mutant. In monocytic THP-1 cells, the R143A virus, but not the wild-type virus, suppressed cGAS-dependent innate immune activation. These results suggest that capsid stabilization improves the shielding of viral DNA from innate sensing. We found that a naturally occurring transmitted founder (T/F) variant shares the same properties as the R143A mutant with respect to PF74 resistance and DNA sensing. Imaging assays revealed delayed uncoating kinetics of this T/F variant and the R143A mutant. All these phenotypes of this T/F variant were controlled by a genetic polymorphism located at the trimeric interface between capsid hexamers, thus linking these capsid-dependent properties. Overall, this work functionally connects capsid stability to innate sensing of viral DNA and reveals naturally occurring phenotypic variation in HIV-1 capsid stability.IMPORTANCE The HIV-1 capsid, which is made from individual viral capsid proteins (CA), is a target for a number of antiviral compounds, including the small-molecule inhibitor PF74. In the present study, we utilized PF74 to identify a transmitted/founder (T/F) strain that shows increased capsid stability. Interestingly, PF74-resistant variants prevented cGAS-dependent innate immune activation under a condition where the other T/F strains induced type I interferon. These observations thus reveal a new CA-specific phenotype that couples capsid stability to viral DNA recognition by cytosolic DNA sensors.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  capsid; human immunodeficiency virus

Mesh:

Substances:

Year:  2019        PMID: 31167922      PMCID: PMC6675898          DOI: 10.1128/JVI.00706-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  107 in total

1.  Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells.

Authors:  S Tang; T Murakami; B E Agresta; S Campbell; E O Freed; J G Levin
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  Functional surfaces of the human immunodeficiency virus type 1 capsid protein.

Authors:  Uta K von Schwedler; Kirsten M Stray; Jennifer E Garrus; Wesley I Sundquist
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication.

Authors:  T Fitzon; B Leschonsky; K Bieler; C Paulus; J Schröder; H Wolf; R Wagner
Journal:  Virology       Date:  2000-03-15       Impact factor: 3.616

4.  Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication.

Authors:  Brett M Forshey; Uta von Schwedler; Wesley I Sundquist; Christopher Aiken
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Association of Nef with the human immunodeficiency virus type 1 core.

Authors:  A Kotov; J Zhou; P Flicker; C Aiken
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

6.  Capsid is a dominant determinant of retrovirus infectivity in nondividing cells.

Authors:  Masahiro Yamashita; Michael Emerman
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.

Authors:  Véronique Zennou; Paul D Bieniasz
Journal:  Virology       Date:  2006-02-07       Impact factor: 3.616

8.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

9.  Characterization of intracellular reverse transcription complexes of Moloney murine leukemia virus.

Authors:  A Fassati; S P Goff
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

10.  Evidence for direct involvement of the capsid protein in HIV infection of nondividing cells.

Authors:  Masahiro Yamashita; Omar Perez; Thomas J Hope; Michael Emerman
Journal:  PLoS Pathog       Date:  2007-10-26       Impact factor: 6.823

View more
  14 in total

1.  Murine Leukemia Virus P50 Protein Counteracts APOBEC3 by Blocking Its Packaging.

Authors:  Wenming Zhao; Charbel Akkawi; Marylène Mougel; Susan R Ross
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

2.  Capsid Lattice Destabilization Leads to Premature Loss of the Viral Genome and Integrase Enzyme during HIV-1 Infection.

Authors:  Jenna E Eschbach; Jennifer L Elliott; Wen Li; Kaneil K Zadrozny; Keanu Davis; Shawn J Mohammed; Dana Q Lawson; Owen Pornillos; Alan N Engelman; Sebla B Kutluay
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

3.  Absence of cGAS-mediated type I IFN responses in HIV-1-infected T cells.

Authors:  Carina Elsner; Aparna Ponnurangam; Julia Kazmierski; Thomas Zillinger; Jenny Jansen; Daniel Todt; Katinka Döhner; Shuting Xu; Aurélie Ducroux; Nils Kriedemann; Angelina Malassa; Pia-Katharina Larsen; Gunther Hartmann; Winfried Barchet; Eike Steinmann; Ulrich Kalinke; Beate Sodeik; Christine Goffinet
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-24       Impact factor: 11.205

4.  Vpx enhances innate immune responses independently of SAMHD1 during HIV-1 infection.

Authors:  Oya Cingöz; Nicolas D Arnow; Mireia Puig Torrents; Norbert Bannert
Journal:  Retrovirology       Date:  2021-02-09       Impact factor: 4.602

5.  Toll-Like Receptor (TLR) Signaling Enables Cyclic GMP-AMP Synthase (cGAS) Sensing of HIV-1 Infection in Macrophages.

Authors:  Mohammad Adnan Siddiqui; Masahiro Yamashita
Journal:  mBio       Date:  2021-11-30       Impact factor: 7.867

Review 6.  Sensor Sensibility-HIV-1 and the Innate Immune Response.

Authors:  Xin Yin; Simon Langer; Zeli Zhang; Kristina M Herbert; Sunnie Yoh; Renate König; Sumit K Chanda
Journal:  Cells       Date:  2020-01-20       Impact factor: 6.600

Review 7.  HIV Capsid Inhibitors Beyond PF74.

Authors:  Carole McArthur; Fabio Gallazzi; Thomas P Quinn; Kamal Singh
Journal:  Diseases       Date:  2019-10-30

8.  HIV-1 Uncoating and Nuclear Import Precede the Completion of Reverse Transcription in Cell Lines and in Primary Macrophages.

Authors:  Ashwanth C Francis; Mariana Marin; Mathew J Prellberg; Kristina Palermino-Rowland; Gregory B Melikyan
Journal:  Viruses       Date:  2020-10-30       Impact factor: 5.048

Review 9.  HIV-1 Maturation: Lessons Learned from Inhibitors.

Authors:  Alex B Kleinpeter; Eric O Freed
Journal:  Viruses       Date:  2020-08-26       Impact factor: 5.048

10.  Disrupting HIV-1 capsid formation causes cGAS sensing of viral DNA.

Authors:  Rebecca P Sumner; Lauren Harrison; Emma Touizer; Thomas P Peacock; Matthew Spencer; Lorena Zuliani-Alvarez; Greg J Towers
Journal:  EMBO J       Date:  2020-08-27       Impact factor: 14.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.